Macrogenics (MGNX) Operating Margin (2012 - 2026)
Macrogenics (MGNX) posted quarterly Operating Margin of 160.96% for Q1 2026, up 16215.0% year-over-year from N/an in Q1 2025, and down 448.55% quarter-over-quarter from 29.34% in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Operating Margin (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Operating Margin for 15 consecutive years, with 160.96% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 16215.0% year-over-year to 160.96%; the TTM figure through Mar 2026 stood at 40.53% (up 1640.0% YoY), while the FY2025 annual figure was 48.72%, up 2501.0% from the prior year.
- Operating Margin slipped to 160.96% in Q1 2026 per MGNX's latest filing, from 29.34% in the prior quarter.
- Across five years, Operating Margin topped out at 48.95% in Q3 2024 and bottomed at 600.29% in Q1 2022.
- Historically, Operating Margin has averaged 233.59% across 5 years, with a median of 160.96% in 2026.
- On a YoY basis, Operating Margin climbed as much as 44342 bps in 2023 and fell as far as 47678 bps in 2023.
- Macrogenics' Operating Margin stood at 16.39% in 2022, then slumped by 2908 bps to 460.39% in 2023, then jumped by 71 bps to 132.09% in 2024, then surged by 78 bps to 29.34% in 2025, then slumped by 449 bps to 160.96% in 2026.
- Business Quant data shows MGNX's Operating Margin at 160.96% in Q1 2026, 29.34% in Q4 2025, and 25.59% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | -42.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.19% |
| Mar 31, 2026 | -160.96% |
| Dec 31, 2025 | -29.34% |
| Sep 30, 2025 | 25.59% |
| Jun 30, 2025 | -629.26% |
| Mar 31, 2025 | -323.10% |
| Dec 31, 2024 | -132.09% |
| Sep 30, 2024 | 48.95% |
| Jun 30, 2024 | -538.86% |
| Mar 31, 2024 | -590.40% |
| Dec 31, 2023 | -460.39% |
| Sep 30, 2023 | -341.46% |
| Jun 30, 2023 | -342.28% |
| Mar 31, 2023 | -156.87% |
| Dec 31, 2022 | 16.39% |
| Sep 30, 2022 | -59.80% |
| Jun 30, 2022 | -160.76% |
| Mar 31, 2022 | -600.29% |
| Dec 31, 2021 | -411.65% |
| Sep 30, 2021 | -338.32% |